A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

Site Image

Study Overview

    The research study is being conducted to see how well the investigational drug, Nefecon, works for the treatment of your kidney disease and more specific for patients with "primary immunoglobulin A nephropathy," called IgAN.

    • Study Identifier: 833614

    Recruitment Status

    Open

    Contact the research team to learn more about this study.

    Fields marked with asterisk (*) are required

    Please verify that you are not a bot.

    By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

    Volunteer Sign up

    Volunteer Sign-up

    Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

    Sign Up Now!

    If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu